Everolimus and Low-Dose Tacrolimus Therapy After Pediatric Heart Transplant: Insights from a Multicenter Randomized Clinical Trial

Everolimus and Low-Dose Tacrolimus Therapy After Pediatric Heart Transplant: Insights from a Multicenter Randomized Clinical Trial

This randomized trial evaluates the safety and efficacy of everolimus combined with low-dose tacrolimus versus standard immunosuppression in children 6 months post-heart transplant, highlighting comparable rejection rates, improved kidney function, and reduced CMV infection risk.
Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes

Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes

This study reveals that prolonged hospitalization after hematopoietic cell transplantation correlates with worse quality of life, greater symptom burden, increased depressive symptoms, and higher risk of rehospitalization and mortality within one year post-transplant.
Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide

Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide

Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for underrepresented patient groups.